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to this. According to the previous literature, body mass 
index (BMI), inflammatory bowel disease, alcoholism, 
tumor grade, lymph nodes metastasis, the degree of 
intestinal wall metastasis, metastasis of other organs, 
and tumor stage affect the survival of the patients 
while BMI, type of the first treatment, and metastasis 
of lymph nodes and other organs contribute to the time 
of death from CRC and hence it could be said that the 
effect of risk factors on different sections of colon is 
different and should be investigated separately.[3] An 
increasing number of epidemiologic Researches have 
found that diabetes mellitus (DM) may change the risk 
of developing a variety of cancers. Higher insulin levels 
may contribute to increased tumor Growth.[2] In another 
study, mean survival time of patients with colon cancer 
was estimated 7.75 ± 1.118 years and that of patients with 
rectum cancer 3.917 ± 0.26.[3] In a research conducted on 
female patients with CRC, longer survival was more 
likely in patients with no history of inflammatory bowel 
INTRODUCTION
Today, cancer is one of the important, fundamental 
problems in health and treatment worldwide, and its 
importance is increasing in countries. Colorectal cancer 
(CRC) is the most prevalent gastrointestinal cancer and 
the cause of 10% of the cancer mortalities. In Iran, the 
frequency rate of CRC has been considerably increasing 
in recent year. Different genetic and environmental 
factors contribute to the development of this cancer.[1] 
In addition, lifestyle is an important risk factor for the 
increased risk of CRC development. Low activity, 
inappropriate diet, smoking, suffering from metabolic 
syndrome (obesity, diabetes, hypertension, and 
dyslipidemia) alongside past medical and family history 
of cancer development, and polyp are among the risk 
factors of CRC occurrence.[2] In recent years, survival 
of CRC patients has enhanced in some regions of the 
world, and it is not clear which factors have contributed 
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disease, distinguished, weak tumor grade, and tumor 
pathologic with stage one.[4] Type 2 DM and hypertension 
are a worldwide epidemic. Worldwide, approximately 
1 billion people have hypertension, contributing to 
>7.1 million deaths per year. The increase in the rate of 
hypertension and type 2 DM could be attributed to the 
aging of the population, obesity prevalence, salt intake, 
sedentary life, urbanization, and socioeconomic changes. 
Patients with diabetes and hypertension are at a higher risk 
than the general population of developing cancer. There 
is a growing body of evidence published in recent years 
that suggest a substantial increase in cancer incidence in 
diabetic patients. The worldwide prevalence of diabetes was 
estimated to rise from 171 million in 2000 to 366 million in 
2030. About 26.9% of all people over 65 have diabetes, and 
60% have cancer. Overall, 8-18% of cancer patients have 
diabetes.[5-10] In Iran, prevalence of hypertension and type 2 
DM in patients with CRC are unknowns. The present study 
was aimed to investigate the prevalence of hypertension 
and type 2 DM and their effect on median survival time in 
patients with CRC.
MATERIALS AND METHODS
In this study we analyzed the data of a prospective, cohort 
study conducted by Gastroenterology and Liver Disease 
Research Center affiliated to Shahid Beheshti University of 
Medical Sciences. The study population was patients with 
diagnosed CRC from 10 gastrointestinal clinics. Informed, 
written consent was obtained from all the patients and 
the design of the study was approved by Shahid Beheshti 
University Ethics Committee (approval no. 676). The 
patients were followed-up from definite diagnosis of CRC 
till death or completion of the study or their censoring once 
each 6 months. Overall, 2570 individual-year follow-ups 
were conducted for 1127 patients with CRC. The study 
was initiated at September 23, 2006, and the patients 
were followed-up until October 23, 2011. CRC diagnosis 
was determined according to criteria of International 
Classification of Pathologies and Diseases, the pathology 
report, and criteria of American Commission on Cancer. 
The final outcome in patients was asked through telephone 
contact. The required data were obtained from 98% of 
the patients. The test for diagnosing type 2 diabetes and 
hypertension were done at enrollment of the participants. 
Diagnosis of the above disease has been made at first stage of 
cancer. For the diagnosis of type 2 DM, fasting blood sugar 
test and glycosylated hemoglobin test were used and for that 
of hypertension, blood pressure (BP) was measured in two 
turns. BP was measured twice at 5 min interval by a mercury 
sphygmomanometer. KorotKoff first and fifth phase sounds 
were recorded as systolic and diastolic BP. The average of 
these four readings was used for analyses. Hypertension 
is defined as BP in excess of 140/90 mm Hg. HbA1c was 
measured using column chromatography method with 
Nyco card reader II made in Norway. Fetal bovine serum 
was measured using a spectrophotometer by Erba-XL 300 
made in Germany. We estimated and graphed survival 
curves using the Kaplan-Mier method for CRC patients 
with DM, hypertension and both of them separately. We also 
compared survival curves of these groups of patients with 
log-rank test. To calculated prevalence and data analysis 
was used stata software (Stata Corp. 2011. Stata Statistical 
Software: Release 12. College Station, TX: Stata Corp LP). 
P > 0.05 were considered to be significant (P < 0.05).
RESULTS
Mean age of the patients at diagnosis was 53.38 (standard 
deviation [SD]: 14.3) years and the mean tumor size was 53.35 
(SD: 31.9) mm. 30.2% of the patients were under 45-year-old, 
45.5% between 45 and 65-year-old, and 24.2% over 65-year-
old. 61.3% of the patients (n: 690) were male. According to the 
histopathological diagnosis 55.5% of the patients were in grade 
one, 35.7% in grade two, 8.8% in grade three and four of the 
disease. Patients’ characteristics for demographic variables and 
mortality rate due to CRC are shown in Table 1. The prevalence 
of hypertension and type 2 DM in the patients with CRC were 
respectively 13.38% and 8.69%. The prevalence and confidence 
interval (CI) of hypertension and type 2 DM are shown in 
Table 2. Mean and median survival time with CI is shown in 
Table 3. According to log-rank test, no significant difference 
was observed between the survival time of CRC patients 
suffering from hypertension and diabetes type 2 (P = 0.8188). 
Median survival time in patients with hypertension and DM 
were 8.52 and 4.9 years.
Table 1: Patients’ characteristics for demographic variables 
and mortality rate due to CRC
Variable Percent Death Mortality rate CI 95% IMR
Gender
Men 61.3 150 96.9 82.9-113.8
Women 38.7 85 83 67.1-102.7
Marital status
Married 93 197 85.3 74.2-98.1
Nonmarried 7 24 161 107.9-240.3
Grade
I 55.5 66 66.1 51.8-84
II 35.7 63 98.6 77-126
≥III 8.8 20 123.7 79-191
Stage
First stage 45.2 76 70.6 56.4-88.4
Advanced stage 54.8 124 109.8 92-131
Age groups (year)
<45 30.2 73 89 70.8-112
45-65 45.5 99 83 68.6-101
>65 24.3 63 111 87-142
CRC = Colorectal cancer; CI = Confidence interval; IMR = Incidence mortality rate; 
DM = Diabetes mellitus
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DISCUSSION
Colorectal cancer is ranked as the fourth cause of death from 
cancers with 320,600 mortalities in men after lung cancer, 
liver cancer, and gastric cancer and as the third cause of 
death with 288,100 mortalities in women after lung cancer 
and breast cancer in the world.[11,12] In Iran, this cancer has 
been reported to occur in seven per 100,000 individuals.[12,13] 
It seems that rapid growth of CRC in our society could be 
derived from the contribution of environmental factors 
including particular nutritional habits such as increase in 
carbohydrates and fat consumption and decrease in fiber 
intake especially among youth, change of lifestyle, lack of 
sufficient activity and obesity, large numbers of youth in 
society, and possibly involvement of genetic issues.[14] The 
rate of CRC survival in Iran is low compared with advanced 
countries. Income status, alcohol consumption history, 
metastasis, and the approach to diagnosis and treatment are 
among the factors effective on survival rate.[15] Diabetes and 
hypertension are among risk factors for CRC, in this regard, 
there are theories stating that the individuals with diabetes 
are at a higher risk of developing CRC compared with 
healthy individuals and it occurs in men more frequently 
compared with women. In addition decreased short-term 
survival rates were noted among diabetics undergoing 
surgical resection of CRC. The association between glucose-
level and cancer was approximately linear across full 
range of fasting glucose-levels. An increase in 1 mmol/L 
of fasting plasma glucose-levels was associated with risk 
ratio (RR) 1.05 (95% CI; 1.01-1.10) and 1.11 (1.05-1.16) for 
incidental cancer in men and women, respectively. RR was 
1.37 (1.14-1.64, for trend = 0.002) for all-site cancer incidence 
in men (excluding prostate cancer) and 1.42 (1.18-1.74, P for 
trend <0.001) in women.[15-19] Several case-control studies 
have also confirmed the positive association of diabetes 
with CRC occurrence in male patients, which is not the 
case for women. Most recent meta-analysis comprising 24 
studies (8 case control and 16 cohorts) linked diabetes with 
modest increase in risk of CRC, the most common cancer 
of digestive tract in western societies, with RRs 1.26 (95% 
CI; 1.20-1.31).[20-28] Some mechanisms are suggested for the 
increased CRC occurrence in the patients with diabetes in 
comparison to healthy individuals. Diabetes cause slow 
transmission of substance throughout bowel which results 
in retention of intraintestinal toxic substances. Diabetes 
causes production of carcinogenic, biliary acids, the 
increase in blood insulin level causes an increase in tumor 
growth, and delayed transmission of carcinogenic substance 
exacerbates the damage to DNA and other cells.[24] A study of 
diabetic and nondiabetic individuals reported that substance 
transmission in intestine of diabetic individuals is 70-80% 
longer compared with nondiabetic.[25] In other studies, the 
symptoms of constipation in the patients with diabetes were 
more prevalent compared with nondiabetic individuals.[26,28] 
In a study conducted on women with diabetes, these women 
were found to have a higher risk of developing CRC; but 
the survival of the patients with CRC was not affected by 
diabetes, in a way that a same survival of CRC has been 
found for diabetic and nondiabetic individuals.[28] This 
study is consistent with the findings of the present study 
because diabetes had no effect on survival of CRC patients. 
In some studies the effect of hypertension on CRC has 
been measured, showing that the foods causing decline 
in BP, if consumed daily, contribute greatly to decrease in 
CRC occurrence.[29-31] In many studies, the patients with 
CRC and hypertension treated with bevacizumab had a 
higher likelihood of survival compared with the group 
not suffering from hypertension.[32-38] In the present study, 
hypertension had no effect on the survival of the patients 
with CRC and the prevalence of hypertension and diabetes 
type 2 in population under study was estimated 13.38% 
and 8.69%, respectively, while in a study in Malaysia on 
Table 2: The prevalence (P) of hypertension and type 2 DM in first stage of CRC patients
Disease measure Total patients Men Women
Number Prevalence 95% CI Number Prevalence 95% CI Number Prevalence 95% CI
Hypertension 116 13.38 11.1-15.8 46 6.6 5.3-7.5 70 16.01 15.2-16.8
DM 77 8.69 7-10.7 28 4.05 3.7-5.2 49 11.21 11-12.2
Both* 26 3.03 1.9-4.3 10 1.44 1.2-2.3 16 3.66 2.8-4.2
With neither* (CRC) 908 0 0 606 0 0 302 0 0
*Hypertension and DM; CRC = Colorectal cancer; CI = Confidence interval; DM = Diabetes mellitus
Table 3: Mean and median survival time with CI in the patients suffering from hypertension and type 2 DM
Medical situation Survival time P (log-
rank test)Mean 95% CI Median 95% CI
Without hypertension and DM 9.31 7.56-11.06 6.66 5.13-13.1 Reference
Without hypertension and with DM 5.46 4.84-7.07 4.9 3.58-4.91 0.871
With hypertension and without DM 7.69 5.87-10.17 8.52 4.01-8.6 0.638
With hypertension and DM 5.15 3.88-6.42 4.3 3.32-4.85 0.399
Total patients 9.43 7.83-11.02 3.07 6.86-19.53 0.818
CI = Confidence interval; DM = Diabetes mellitus
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138 patients with CRC, the prevalence of diabetes type 2 
and hypertension was obtained 13% and 34.8%, respectively, 
reporting that these two metabolic diseases were associated 
with CRC.[30,31] The researchers found that among patients 
with early stage disease, patients with diabetes or high BP 
had a significantly greater risk of cancer recurrence rate and 
death after treatment. For example, 47.7% of patients who 
did not have diabetes were still alive 5 years after diagnosis 
compared to only 41.3% of patients with diabetes. When the 
researchers looked more closely, they also found that cancer 
recurrence rates at 5 years were approximately 8% higher 
in patients with diabetes or hypertension.
CONCLUSION
Diabetes and hypertension is a high-risk state for several 
diseases, such as CRC. The obtained findings in this study 
indicate that survival time in patients with type 2 DM 
less than Hypertension, but two metabolic diseases (type 
2 DM and hypertension) have no effect on survival rate of 
the patients with CRC and the survival of these patients 
may be dependent on other factors including the site of 
cancer, the stage when the disease is diagnosed to treatment 
commencement, type of treatment, nutrition status, etc.
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